Partnership expands Integrated Biosciences’ partnerships in translational research and Project 8p Foundation’s footprint in therapeutic development
SAN CARLOS, Calif.–(BUSINESS WIRE)–Integrated Biosciences, a biotechnology company pioneering the use of synthetic biology and machine learning to develop next-generation therapeutics for age-related diseases, today announced a strategic partnership with the patient-led Project 8p Foundation to enhance the treatment landscape for chromosome 8p duplication, deletion and inverted duplication deletion (inv/dup/del) disorders. This partnership provides support to enable Integrated Biosciences to characterize and correct the dysregulation of cellular stress responses in 8p cell lines, paving the way for the development of first-in-class, disease-modifying treatments for 8p heroes suffering from complex, megabase-scale rearrangements of the short arm of chromosome 8p.
